WO1993017111A1 - Hepatitis c virus peptides - Google Patents
Hepatitis c virus peptides Download PDFInfo
- Publication number
- WO1993017111A1 WO1993017111A1 PCT/GB1993/000410 GB9300410W WO9317111A1 WO 1993017111 A1 WO1993017111 A1 WO 1993017111A1 GB 9300410 W GB9300410 W GB 9300410W WO 9317111 A1 WO9317111 A1 WO 9317111A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- seq
- arg
- antibody
- dna sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 162
- 241000711549 Hepacivirus C Species 0.000 title description 38
- 102000004196 processed proteins & peptides Human genes 0.000 title description 32
- 229960005486 vaccine Drugs 0.000 claims abstract description 18
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 230000027455 binding Effects 0.000 claims abstract description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 33
- 230000003612 virological effect Effects 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 239000013604 expression vector Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 11
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- 229960005261 aspartic acid Drugs 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 229960002989 glutamic acid Drugs 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 229960002433 cysteine Drugs 0.000 claims description 6
- 235000005772 leucine Nutrition 0.000 claims description 6
- 229960003136 leucine Drugs 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 108020000999 Viral RNA Proteins 0.000 claims description 4
- 235000009697 arginine Nutrition 0.000 claims description 4
- 229960003121 arginine Drugs 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 235000014705 isoleucine Nutrition 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 235000006109 methionine Nutrition 0.000 claims description 4
- 229930182817 methionine Chemical group 0.000 claims description 4
- 235000013930 proline Nutrition 0.000 claims description 4
- 229960002429 proline Drugs 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- 235000008729 phenylalanine Nutrition 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 235000002374 tyrosine Nutrition 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- 239000004474 valine Chemical group 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 abstract description 7
- 238000003018 immunoassay Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 description 58
- 229940024606 amino acid Drugs 0.000 description 57
- 235000001014 amino acid Nutrition 0.000 description 57
- 238000003556 assay Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 239000000523 sample Substances 0.000 description 19
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 10
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 10
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 10
- JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 108010068380 arginylarginine Proteins 0.000 description 9
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- QMKFDEUJGYNFMC-AVGNSLFASA-N Leu-Pro-Arg Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QMKFDEUJGYNFMC-AVGNSLFASA-N 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229920001184 polypeptide Chemical group 0.000 description 7
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108010057821 leucylproline Proteins 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 5
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 5
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- -1 amino, hydroxyl Chemical group 0.000 description 5
- 238000002820 assay format Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000000562 conjugate Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 3
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010078580 tyrosylleucine Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- 125000003290 L-leucino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 2
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- SIGTYDNEPYEXGK-ZANVPECISA-N Ala-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 SIGTYDNEPYEXGK-ZANVPECISA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 1
- RIQBRKVTFBWEDY-RHYQMDGZSA-N Arg-Lys-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RIQBRKVTFBWEDY-RHYQMDGZSA-N 0.000 description 1
- GNKVBRYFXYWXAB-WDSKDSINSA-N Asn-Glu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O GNKVBRYFXYWXAB-WDSKDSINSA-N 0.000 description 1
- AWXDRZJQCVHCIT-DCAQKATOSA-N Asn-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O AWXDRZJQCVHCIT-DCAQKATOSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 1
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 1
- GJHWILMUOANXTG-WPRPVWTQSA-N Gly-Val-Arg Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GJHWILMUOANXTG-WPRPVWTQSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
- JRJLGNFWYFSJHB-HOCLYGCPSA-N Leu-Gly-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRJLGNFWYFSJHB-HOCLYGCPSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
- DBMLDOWSVHMQQN-XGEHTFHBSA-N Met-Ser-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DBMLDOWSVHMQQN-XGEHTFHBSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- CPRLKHJUFAXVTD-ULQDDVLXSA-N Pro-Leu-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CPRLKHJUFAXVTD-ULQDDVLXSA-N 0.000 description 1
- OFGUOWQVEGTVNU-DCAQKATOSA-N Pro-Lys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OFGUOWQVEGTVNU-DCAQKATOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- NAXBBCLCEOTAIG-RHYQMDGZSA-N Thr-Arg-Lys Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O NAXBBCLCEOTAIG-RHYQMDGZSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- FBQHKSPOIAFUEI-OWLDWWDNSA-N Thr-Trp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O FBQHKSPOIAFUEI-OWLDWWDNSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- FRMFMFNMGQGMNB-BVSLBCMMSA-N Tyr-Pro-Trp Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FRMFMFNMGQGMNB-BVSLBCMMSA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N Valylglycine Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003796 diagnosis of exclusion Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- This invention relates to a novel peptide capable of binding to antibody specific for parenterally transmitted non A non B hepatitis (PT-NANBH) in particular (HCV) and the use of such a peptide in an im unoassay for the detection of HCV or a vaccine for its prevention.
- PT-NANBH parenterally transmitted non A non B hepatitis
- HCV non B hepatitis
- Non A non B hepatitis is by definition a diagnosis of exclusion and has generally been employed to describe cases of viral hepatitis infection in human beings that are not due to hepatitis A or B viruses.
- the PT-NANBH virus has also been referred to as Hepatitis C Virus (HCV) .
- HCV Hepatitis C Virus
- the cause of the infection has not been identified although, on clinical and epidemiological grounds, a number of agents have been thought to be responsible as reviewed in Shih et aJL (Prog Liver Pis. , 1986, 8 . , 433-452). In the USA alone, up to 10% of blood transfusions can . result in NANBH which makes it a significant problem.
- GB-A-2 239 245 discloses nucleotide and polypeptide sequences of a viral agent responsible for Post Transfusional NANBH (PT-NANBH) , the core region of this viral agent responsible for PT-NANBH is disclosed within the nucleotide and peptide sequences.
- the core region of the disclosed viral agent responsible for PT-NANBH was not analysed in GB-A-2 239 245. Substantial portions of the core region were used in reco binant polypeptides namely BHC-11 as disclosed in GB-A-2 239 245.
- EP-A-0 445 423 discloses an assay for detecting the presence of an antibody to an HCV antigen by contacting the sample with a polypeptide containing at least one epitope of an HCV antigen. A polypeptide from the putative core region of HCV is used. Specific epitopic regions of the polypeptides are not identified.
- HCV viral peptide having the following sequence (SEQ ID NO'-s: 1 and 2): Tyr-Leu-Leu-Pro-Arg-Arg (YLLPR )
- the present invention also provides a DNA sequence encoding the peptide as defined above.
- the DNA sequence may be synthetic or cloned.
- Preferably the DNA sequence is as set forth in SEQ ID NO:l.
- a novel synthetic peptide has also been synthesised which peptide has improved assay sensitivity and specificity, when compared to the natural peptide as disclosed above, in assays for HCV.
- the present invention also provides a peptide of the general formula I
- X represents Tyrosine, A ⁇ partic Acid, Gluta ic Acid, Leucine or Isoleucine
- X 2 represents Leucine, Cysteine, Aspartic Acid or Glutamic Acid
- X 3 represents Leucine, Valine
- X 4 represents Proline or Methionine
- X 5 represents Arginine, Aspartic Acid, Glutamic Acid, Proline, Cysteine, Phenylalanine, Isoleucine, Asparagine, Glutamine or Methionine;
- X 6 represents Arginine, Aspartic Acid, Glutamic Acid, Serine or Cysteine and wherein the peptide is not of the formula Tyr-Leu-Leu-Pro- Arg-Arg (SEQ ID NO: l and 2) .
- the present invention also provides a DNA sequence encoding the peptide of general formula I, which sequence can be readily ascertained, bearing in mind the degeneracy of the genetic code and codon usage.
- the peptides of the present invention may be used individually, as part of a larger polypeptide and/or as a mixture of peptides with other peptides from the HCV genome, a heterologous genome or topographically related peptides.
- the present invention also provides peptides which comprise the peptides as defined above, namely, SEQ ID NO's: 4 and 5 and SEQ ID NO's: 6 and 7.
- the present invention also provides DNA sequences encoding the peptide as set forth above.
- the DNA sequences are as set forth in SEQ ID NO's: 4 and 6.
- the present invention also provides expression vectors containing the DNA sequences as herein defined, which vectors being capable, in an appropriate host, of expressing the DN sequence to produce the peptides as defined herein.
- the expression vector normally contains control elements of DNA that effect expression of the DNA sequence in an appropriate host. These elements may vary according to the host but usually include a promoter, ribosome binding site, translational start and stop sites, and a transcriptional termination site. Examples of such vectors include plasmids and viruses.
- Expression vectors of the present invention encompass both extrachromosomal vectors and vectors that are integrated into the host cell's chromosome.
- the expression vector may contain the DNA sequence of the present invention optionally as a fusion linked to either the 5'- or 3'-end of the DNA sequence encoding, for example, ⁇ -galactosidase or to the 3'-end of the DNA sequence encoding, for example, the trp E gene.
- the DNA sequence is optionally fused to the polyhedrin coding sequence.
- the present invention also provides a host cell transformed with expression vectors as herein defined.
- host cells of use with the present invention include prokaryotic and eukaryotic cells, such as bacterial, yeast, mammalian and insectcells. Particular examples of such cells are E.coli, S.cerevisiae, P. astoris, Chinese hamster ovary and mouse cells, and Spodoptera frucriperda and Tricoplusia ni.
- the choice of host cell may depend on a number of factors but, if post-translational modification of the HCV viral peptide is important, then an eukaryotic host would be preferred.
- the present invention also provides a process for preparing a peptides as defined herein which comprises isolating the DNA sequence, as herein defined, from the HCV genome, or synthesising DNA sequence encoding the peptides as defined herein, or generating a DNA sequence encoding the peptide of Formula I, inserting the DNA sequence into an expression vector such that it is capable, in an appropriate host, of being expressed, transforming an host cells with the expression vector, culturing the transformed host cells, and isolating the peptide.
- the DNA sequence encoding the peptide may be synthesised using standard procedures (Gait, Oligonucleotide Synthesis: A Practical Approach. 1984, Oxford, IRL Press).
- the desired DNA sequence obtained as described above may be inserted into an expression vector using known and standard techniques.
- the expression vector is normally cut using restriction enzymes and the DNA sequence inserted using blunt- end or staggered-end ligation.
- the cut is usually made at a restriction site in a convenient position in the expression vector such that, once inserted, the DNA sequences are under the control of the functional elements of DNA that effect its expression.
- Transformation of an host cell may be carried out using standard techniques. Some phenotypic marker is usually employed to distinguish between the tran ⁇ formants that have successfully taken up the expression vector and those that have not. Culturing of the transformed host cell and isolation of the peptide as required may also be carried out using standard techniques.
- the peptides of the present invention may be prepared by synthetic methods or by recombinant DNA technology.
- the peptides are preferably synthesized using automatic synthesizers.
- Antibody specific to a peptide of the present invention can be raised using the peptide.
- the antibody may be polyclonal or monoclonal.
- the antibody may be used in quality control testing of batches of the peptides; purification of a peptide or viral lysate; epitope mapping; when labelled, as a conjugate in a competitive type assay, for antibody detection; and in antigen detection assays.
- Polyclonal antibody against a peptide of the present invention may be obtained by injecting a peptide, optionally coupled to a carrier to promote an immune response, into a mammalian host, such as a mouse, rat, sheep or rabbit, and recovering the antibody thus produced.
- the peptide is generally administered in the form of an injectable formulation in which the peptide is admixed with a physiologically acceptable diluent.
- Adjuvants such as Freund's complete adjuvant (FCA) or Freund's incomplete adjuvant (FIA) , may be included in the formulation.
- FCA Freund's complete adjuvant
- FIA Freund's incomplete adjuvant
- FCA Freund's complete adjuvant
- FIA Freund's incomplete adjuvant
- the formulation is normally injected into the host over a suitable period of time, plasma samples being taken at appropriate intervals for assay for anti-HCV viral antibody. When an appropriate level of activity is obtained, the host is bled. Antibody is then extracted and purified from the blood plasma using standard procedures, for example, by protein A or ion-exchange chromatography.
- Monoclonal .antibody against a peptide of the present invention may be obtained by fusing cells of an immortalising cell line with cells which produce antibody against the viral or topographically related peptide, and culturing the fused immortalised cell line.
- an immortalising cell line with cells which produce antibody against the viral or topographically related peptide
- culturing the fused immortalised cell line Typically, a non-human mammalian host, such as a mouse or rat, is inoculated with the peptide. After sufficient time has elapsed for the host to mount an antibody response, antibody producing cells, such as the splenocytes, are removed.
- Cells of an immortalising cell line such as a mouse or rat myeloma cell line, are fused with the antibody producing cells and the resulting fusions screened to identify a cell line, such as a hybridoma, that secretes the desired monoclonal antibody.
- the fused cell line may be cultured and the monoclonal antibody purified from the culture media in a similar manner to the purification of polyclonal antibody.
- Diagnostic assays based upon the present invention may be used to determine the presence or absence of HCV infection. They may also be used to monitor treatment of such infection, for example in interferon therapy.
- an assay for the diagnosis of viral infection there are basically three distinct approaches that can be adopted involving the detection of viral nucleic acid, viral antigen or viral antibody.
- Viral nucleic acid is generally regarded as the best indicator of the presence of the virus itself and would identify materials likely to be infectious. However, the detection of nucleic acid is not usually as straightforward as the detection of antigens or antibodies since the level of target can be very low.
- Viral antigen is used as a marker for the presence of virus and as an indicator of infectivity.
- the amount of antigen present in a sample can be very low and difficult to detect.
- Antibod detection is relatively straightforward because, in effect, the host immune system is amplifying the response to an infection by producing large amounts of circulating antibody. The natur of the antibody response can often be clinically useful, fo example IgM rather than IgG class antibodies are indicative o a recent infection, or the response to a particular vira antigen may be associated with clearance of the virus. Thu the exact approach adopted for the diagnosis of a vira infection depends upon the particular circumstances and th information sought. In the case of HCV, a diagnostic assay ma embody any one of these three approaches.
- the method may comprise hybridisin viral RNA present in a test sample, or cDNA synthesised fro such viral RNA, with a DNA sequence corresponding to th nucleotide sequence of SEQ ID NO: 1, 4 or 6 or encoding th peptide of formula I and screening the resulting nucleic aci hybrids to identify any HCV viral nucleic acid.
- Th application of this method is usually restricted to a tes sample of an appropriate tissue, such as a liver* biopsy, i which the viral RNA is likely to be present at a high level
- the DNA sequence corresponding to the nucleotide sequence o SEQ ID NO: l, 4 or 6 or encoding the peptide of Formula I ma take the form of an oligonucleotide or a cDNA sequenc sequence optionally contained within a plasmid. Screening of the nucleic acid hybrids is preferably carried out by using a labelled DNA sequence.
- the peptide of the present invention is part of an oligonucleotide wherein the label is situated at a sufficient distance from the peptide so that binding of the peptide to the viral nucleic acid is not interfered with by virtue of the label being too close to the binding site.
- One or more additional rounds of screening of one kind or another may be carried out to characterise further the hybrids and thus identify any HCV viral nucleic acid. The steps of hybridisation and screening are carried out in accordance with procedures known in the art.
- the present invention also provides a test kit for the detection of HCV viral nucleic acid, which comprises
- a labelled oligonucleotide comprising a DNA sequence corresponding to the nucleotide sequence of SEQ ID NO: 1, 4 or 6 or encoding the peptide of formula I; and optionally;
- test kit also contains a positive control sample to facilitate in the identification of viral nucleic acid.
- the method may comprise contacting a test sample with a peptide of the present invention or a polyclonal or monoclonal antibody against the peptide and determining whether there is any antigen-antibody binding contained within the test sample.
- a test kit may be provided comprising a peptide, as defined herein, or a polyclonal or monoclonal antibody thereto and means for determining whether there is any binding with antibody or antigen respectively contained in the test sample.
- the test sample may be taken from any of the appropriate tissues and physiological fluids mentioned above for the detection of viral nucleic acid. If a physiological fluid is obtained, it may optionally be concentrated for any viral antigen or antibody present.
- the peptide can be used to capture selectively antibody against HCV from solution, to label selectively the antibody already captured, or both to capture and label the antibody.
- the peptide may be used in a variety of homogeneous assay formats in which the antibody reactive with the peptide is detected in solution with no separation of phases.
- the types of assay in which the peptide is used to capture antibody f om solution involve immobilization of th peptide on to a solid surface. This surface should be capabl of being washed in some way.
- suitable surfaces include polymers of various types (moulded into microtitr wells; beads; dipsticks of various types; aspiration tips; electrodes; and optical devices) , particles (for example latex; stabilized red blood cells; bacterial or fungal cells; spores; gold or other metallic or metal-containing sols; an proteinaceous colloids) with the usual size of the particl being from 0.02 to 5 microns, membranes (for example o nitrocellulose; paper; cellulose acetate; and hig porosity/high surface area membranes of an organic or inorgani material) .
- the attachment of the peptide to the surface can be b passive adsorption from a solution of optimum composition whic may include surfactants, solvents, salts and/or chaotropes; o by active chemical bonding.
- Active bonding may be through variety of reactive or activatible functional groups which ma be exposed on the surface (for example condensing agents active acid esters, halides and anhydrides; amino, hydroxyl, o carboxyl groups; sulphydryl groups; carbonyl groups; diazo groups; or unsaturated groups) .
- the active bonding may be through a protein (itself attached to the surface passively or through active bonding) , such as albumin or casein, to which the viral peptide may be chemically bonded by any of a variety of methods.
- a protein in this way may confer advantages because of isoelectric point, charge, hydrophilicity or other physico-chemical property.
- the viral peptide may also be attached to the surface (usually but not necessarily a membrane) following electrophoretic separation of a reaction mixture, such as immuno precipitation.
- the captured antibody After contacting (reacting) the surface bearing the peptide with a test sample, allowing time for reaction, and, where necessary, removing the excess of the sample by any of a variety of means, (such as washing, centrif gation, filtration, magnetism or capilliary action) the captured antibody is detected by any means which will give a detectable.signal.
- this may be achieved by use of a labelled molecule or particle as described above which will react with the captured antibody (for example protein A or protein G and the like; anti-species or anti-immunoglobulin-sub-type; rheumatoid factor; or antibody to the peptide, used in a competitive or blocking fashion) , or any molecule containing an epitope contained in the peptide.
- the captured antibody for example protein A or protein G and the like; anti-species or anti-immunoglobulin-sub-type; rheumatoid factor; or antibody to the peptide, used in a competitive or blocking fashion
- the detectable signal may be optical or radioactive or physico-chemical and may be provided directly by labelling the molecule or particle with, for example, a dye,- radiolabel,. electroactive species, magnetically resonant species or fluorophore, or indirectly by labelling the molecule or particle with an enzyme itself capable of giving rise to a measurable change of any sort.
- the detectable signal may be obtained using, for example, agglutination, or- through a diffraction or birefringent effect if the surface is in the form of particles.
- Assays in which a peptide itself is used to label an already captured antibody require some form of labelling of the peptide which will allow it to be detected.
- the labelling may be direct by chemically or passively attaching for example a radio label, magnetic resonant species, particle or enzyme label to the peptide; or indirect by attaching any form of label to a molecule which will itself react with the peptide.
- the chemistry of bonding a label to the peptide can be directly through a moiety already present in the peptide, such as an amino group, or through an intermediate moiety, such as a maleimide group.
- Capture of the antibody may be on any of the surfaces already mentioned by any reagent including passive or activated adsorption which will result in specific antibody or immune complexes being bound.
- capture of the antibody could be by anti-species or anti-immunoglobulin-sub- type, by rheumatoid factor, proteins A, G and the like, or by any molecule containing an epitope contained in the peptide.
- the labelled peptide may be used in a competitive binding fashion in which its binding to any specific molecule on any of the surfaces exemplified above is blocked by antigen in the sample. Alternatively, it may be used in a non-competitive fashion in which antigen in the sample is bound specifically or non-specifically to any of the surfaces above and is also bound to a specific bi- or poly-valent molecule (e.g. an antibody) with the remaining valencies being used to capture the labelled peptide.
- a specific bi- or poly-valent molecule e.g. an antibody
- the peptide and an antibody are separately labelled so that, when the antibody reacts with the recombinant peptide in free solution, the two labels interact to allow, for example, non-radiative transfer of energy captured by one label to the other label with appropriate detection of the excited second label or quenched first label (e.g. by fluorimetry, magnetic resonance or enzyme measurement) .
- Addition of either viral peptide or antibody in a sample results in restriction of the interaction of the labelled pair and thus in a different level of signal in the detector.
- a suitable assay format for detecting HCV antibody is the direct sandwich enzyme immunoassay (EIA) format.
- EIA direct sandwich enzyme immunoassay
- a peptide is coated onto microtitre wells.
- a test sample and a peptide to which an enzyme is coupled are added simultaneously. Any HCV antibody present in the test sample binds both to the peptide coating the well and to the enzyme-coupled peptide. Typically, the same peptide are used on both sides of the sandwich. After washing, bound enzyme is detected using a specific substrate involving a colour change.
- a test kit for use in such an EIA comprises:
- washing solutions and/or buffers optionally, washing solutions and/or buffers.
- IgG/IgM antibody capture ELISA wherein an antihu an antibody is coated onto microlitre wells, a test sample is added to the well. Any IgG or IgM antibody present in the test sample will then bind to the anti-human antibody.
- a peptide of the present invention, which has been labelled, is added to the well and the peptide will bind to any IgG or IgM antibody which has resulted due to infection by HCV.
- the IgG or IgM antibody can be visualized by virtue of the label on the peptide.
- the peptides of the present invention may be used for the detection of HCV infection in many formats, namely as free peptides, in assays including classic ELISA, competition ELISA, membrane bound EIA and immunoprecipitation.
- Peptide conjugates may be used in amplified assays and IgG/IgM antibody capture ELISA.
- the peptide of the present invention may be incorporated into a vaccine formulation for inducing immunity to HCV in man.
- the peptide may be presented in association with a pharmaceutically acceptable carrier.
- the peptide may optionally be presented as part of an hepatitis B core fusion particle, as described in Clarke et al (Nature, 1987, 330. 381- 384) , or a polylysine based polymer, as described in Tarn (PNAS, 1988, 8J5. 5409-5413).
- the peptide may optionally be attached to a particulate structure, such as liposomes or ISCOMS.
- Pharmaceutically acceptable carriers include liquid media suitable for use as vehicles to introduce the peptide into a patient.
- liquid media is saline solution.
- the peptide may be dissolved or suspended as a solid in the carrier.
- the vaccine formulation may also contain an adjuvant for stimulating the immune response and thereby enhancing the effect of the vaccine.
- adjuvants include aluminium hydroxide and aluminium phosphate.
- the vaccine formulation may contain a final concentration of peptide in the range from 0.01 to 5 mg/ml, preferably from 0.03 to 2 mg/ml.
- the vaccine formulation may be incorporated into a sterile container, which is then sealed and stored at a low temperature, for example 4°C, or may be freeze-dried.
- one or more doses of the vaccine formulation may be administered.
- Eac dose may be 0.1 to 2 ml, preferably 0.2 to 1 ml.
- a method fo inducing immunity to HCV in man comprises the administratio of an effective amount of a vaccine formulation, as hereinbefore defined.
- the present invention also provides the use of a peptide as herein defined in the preparation of a vaccine for use in the induction of immunity to HCV in man.
- Vaccines of the present invention may be administered by any convenient method for the administration of vaccines including oral and parenteral (e.g. intravenous, subcutaneous or intramuscular) injection.
- the treatment may consist of a single dose of vaccine or a plurality of doses over a period of time.
- HCV Core protein SEQ ID NO: 8 The N-terminal 97 amino acid residues of HCV Core protein SEQ ID NO: 8 was mapped with PEPSCAN analysis. This process involved the serological analysis of sequentially overlapping peptides which spanned the region of interest, to identify epitopic domains.
- Ninety overlapping octameric peptides were synthesized on polypropylene pin supports according to the manufacturer's instructions (Cambridge Research Biochemicals) , such that each peptide overlapped with the preceding sequence by the seven N-terminal residues, and with the subsequent peptide by the seven C-terminal residues.
- Serum or IgG purified from the serum of individuals confirmed to be seropositive for HCV were used to screen the peptides.
- Example 2 Screening of the Peptides
- the assay procedure followed was performed basically as described in the manufacturers instruction manual.
- the time and temperature of the test antibody incubation differed from that prescribed, thereby decreasing the time taken for each assay.
- Sera A total of 16 sera were assayed by PEPSCAN. These consisted of 12 sera from paid U.S. Donors which were identified as being positive for antibodies against HCV in routine screening at the site of donation. The remaining four sera were from patients diagnosed as having non-A non-B hepatitis, and which were subsequently shown to contain antibodies to HCV. Sera were screened either as the crude serum fraction, or as a caprylic acid preparation. Caprylic acid purification of IgG from the sera was performed as described by Stienbuch and Audran (1969) Arch. Biochem. Biophys. 134, 279-284.
- the assay format involves sequentially incubating the various pins in microwell plates containing blocking, test antibody, conjugate, and substrate solutions.
- the immune complex builds up on the pin with the enzyme labelled conjugate being immobilized on the bound anti-peptide antibody from the test serum.
- the enzyme brings about the colour change which is used to quantify the amount of anti-peptide antibody bound.
- Pins are immersed in 200 ⁇ l of Supercocktail (1% Ovalbu in, 1% bovine serum albumin in 0.15M phosphate buffered saline pH 7.2 + 0.1% Tween 20) and left to stand at room temperature for 1 hour.
- Supercocktail 1% Ovalbu in, 1% bovine serum albumin in 0.15M phosphate buffered saline pH 7.2 + 0.1% Tween 20
- Test antibody The test antibody is diluted between 1/200 (IgG) and 1/1000 (serum) in supercocktail. The pins are then stood in .this solution (175 ⁇ l/well) at 37°C for 1 hour. After this incubation the pins are washed four times in 0.15M phosphate buffered saline pH 7.2 + 0.05% Tween 20, each at room temperature for 10 minutes.
- Substrate The substrate solution is made up fresh for each assay. To 100ml of 0.1M phosphate, 0.08M citrate buffer pH 4.0 is dissolved 50mg of 2,2 ⁇ -AZIN0-bis(3-ethylbenzthiazo- linsulphonic acid (ABTS) and 0.3 ⁇ l/ml 30% hydrogen peroxide is added. The pins are immersed in the wells containing substrate solution (150 ⁇ l/well) and incubated at room temperature in the dark. Once sufficient colour has developed the reaction is stopped by removing the pins. The plates are then read immediately in a spectrophotometric plate reader at a wavelength of 405nm. The absorbance values are then plotted against pin number. The epitopic domains are then defined as the continuous sequence of amino acids common to all positive pins in the domain i.e.
- the epitope has the sequence Tyr-Leu-Leu-Pro- Arg-Arg (YLLPRR) (SEQ ID NO's: l and 2).
- pins are cleaned by ultrasonication in disruption buffer (1% sodium dodecyl sulphate, 0.1% 2- mercaptoethanol in 0.1M sodium dihydrogen phosphate) heated to 60°C. Pins are sonicated for 30 minutes and then washed twice in distilled water at 60°C and once in boiling methanol. Pins can then be stored at room temperature sealed in bags containing silica gel, or can be re-used immediately for the next assay.
- disruption buffer 1% sodium dodecyl sulphate, 0.1% 2- mercaptoethanol in 0.1M sodium dihydrogen phosphate
- the Replacement Net Method was used to sequentially replace each of the constituent amino acid residues in the epitope with each of the other genetically encoded amino acids.
- each replacement residue As an acceptable replacement for the parent sequence is given. Replacement residues were deemed acceptable when the signal of the new peptide was 80% of the parent sequence or greater.
- HMP resin p- hydroxy ethylphenoxymethyl (HMP) resin by stepwise solid phase synthesis (proceeding from the carboxyl terminal residue towards the amino terminal residue) according to the general procedure set out in Applied Biosystems User Bulletin No 33, November 1990.
- HMP resin was transferred into the reaction vessel of an Applied Biosystems Peptide Synthesizer Model 431A. ⁇ r ⁇ . carboxyl-terminal amino acid residue was coupled to the resin using the standard Applied Biosystems Fastmoc cycle, protocol. Unreacted coupling sites on the resin were then blocked by capping with benzoic anhydride.
- the fully protected peptide-resin was transferred to a pear-shaped flask and treated with ethanedithiol (0.25 ml), thioanisole (0.5 ml), water (0.5 ml) and TFA (8.75 ml). -The mixture was stirred for 90 minutes at room temperature, then filtered through glass wool in a Pasteur pipette. The filtrate was dropped into ice-cold ether, contained in a Corex centrifuge tube, whereupon the peptide precipitated. The tube was centrifuged and the liquor aspirated to leave the peptide pellet in the tube.
- a vaccine formulation may be prepared by conventional techniques using the following constituents in the indicated amounts.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK1035-94A SK103594A3 (en) | 1992-02-28 | 1993-01-01 | Hepatitis "c" virus peptides |
JP5514676A JPH07504562A (en) | 1992-02-28 | 1993-02-26 | Hepatitis C virus peptide |
AU35725/93A AU688259B2 (en) | 1992-02-28 | 1993-02-26 | Hepatitis C virus peptides |
EP93904270A EP0628079A1 (en) | 1992-02-28 | 1993-02-26 | Hepatitis c virus peptides |
FI943929A FI943929A0 (en) | 1992-02-28 | 1994-08-26 | Hepatitis C virus peptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9204274.6 | 1992-02-28 | ||
GB929204274A GB9204274D0 (en) | 1992-02-28 | 1992-02-28 | Novel peptides |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08295721 A-371-Of-International | 1994-08-29 | ||
US84211497A Continuation | 1992-02-28 | 1997-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993017111A1 true WO1993017111A1 (en) | 1993-09-02 |
Family
ID=10711198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/000410 WO1993017111A1 (en) | 1992-02-28 | 1993-02-26 | Hepatitis c virus peptides |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0628079A1 (en) |
JP (1) | JPH07504562A (en) |
AU (1) | AU688259B2 (en) |
CA (1) | CA2131028A1 (en) |
CZ (1) | CZ285834B6 (en) |
FI (1) | FI943929A0 (en) |
GB (1) | GB9204274D0 (en) |
SK (1) | SK103594A3 (en) |
WO (1) | WO1993017111A1 (en) |
ZA (1) | ZA931299B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011307A1 (en) * | 1993-10-22 | 1995-04-27 | Institut Pasteur | Nucleotide vector, composition containing such vector and vaccine for immunization against hepatitis |
EP0829488A1 (en) * | 1995-04-28 | 1998-03-18 | Srl, Inc. | Antigen peptide compound and immunoassay method |
FR2775690A1 (en) * | 1998-03-09 | 1999-09-10 | Bio Merieux | Monoclonal antibodies useful for detecting and/or quantifying hepatitis C virus core protein |
EP1083428A2 (en) * | 1999-08-19 | 2001-03-14 | Kyowa Medex Co., Ltd. | Method and reagent for the detection or determination of HCV core antigens |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014436A1 (en) * | 1989-05-18 | 1990-11-29 | Chiron Corporation | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus |
EP0442394A2 (en) * | 1990-02-16 | 1991-08-21 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines |
WO1993000365A2 (en) * | 1991-06-24 | 1993-01-07 | Chiron Corporation | Hepatitis c virus (hcv) polypeptides |
-
1992
- 1992-02-28 GB GB929204274A patent/GB9204274D0/en active Pending
-
1993
- 1993-01-01 SK SK1035-94A patent/SK103594A3/en unknown
- 1993-02-24 ZA ZA931299A patent/ZA931299B/en unknown
- 1993-02-26 JP JP5514676A patent/JPH07504562A/en active Pending
- 1993-02-26 EP EP93904270A patent/EP0628079A1/en not_active Withdrawn
- 1993-02-26 WO PCT/GB1993/000410 patent/WO1993017111A1/en not_active Application Discontinuation
- 1993-02-26 AU AU35725/93A patent/AU688259B2/en not_active Ceased
- 1993-02-26 CZ CZ942068A patent/CZ285834B6/en not_active IP Right Cessation
- 1993-02-26 CA CA002131028A patent/CA2131028A1/en not_active Abandoned
-
1994
- 1994-08-26 FI FI943929A patent/FI943929A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014436A1 (en) * | 1989-05-18 | 1990-11-29 | Chiron Corporation | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus |
EP0442394A2 (en) * | 1990-02-16 | 1991-08-21 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines |
WO1993000365A2 (en) * | 1991-06-24 | 1993-01-07 | Chiron Corporation | Hepatitis c virus (hcv) polypeptides |
Non-Patent Citations (2)
Title |
---|
LABORATORY INVESTIGATION vol. 65, no. 4, 1991, pages 408 - 411 Y. SHIEH ET AL. 'Detection of hepatitis C virus sequences in liver tissue by the polymerase chain reaction' * |
PROC. NAT'L. ACAD. SCI. USA vol. 88, no. 12, 1991, pages 5462 - 5466 M. NASOFF ET AL. 'Identification of an immunodominant epitope within the capsid protein of hepatitis C virus' * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011307A1 (en) * | 1993-10-22 | 1995-04-27 | Institut Pasteur | Nucleotide vector, composition containing such vector and vaccine for immunization against hepatitis |
FR2711670A1 (en) * | 1993-10-22 | 1995-05-05 | Pasteur Institut | Nucleotide vector, composition containing it and vaccine for immunization against hepatitis. |
US7825097B2 (en) | 1993-10-22 | 2010-11-02 | Institut Pasteur | Nucleotide vector vaccine for immunization against hepatitis |
EP0829488A1 (en) * | 1995-04-28 | 1998-03-18 | Srl, Inc. | Antigen peptide compound and immunoassay method |
EP0829488A4 (en) * | 1995-04-28 | 1999-04-07 | Srl Inc | Antigen peptide compound and immunoassay method |
FR2775690A1 (en) * | 1998-03-09 | 1999-09-10 | Bio Merieux | Monoclonal antibodies useful for detecting and/or quantifying hepatitis C virus core protein |
EP1083428A2 (en) * | 1999-08-19 | 2001-03-14 | Kyowa Medex Co., Ltd. | Method and reagent for the detection or determination of HCV core antigens |
EP1083428A3 (en) * | 1999-08-19 | 2001-05-16 | Kyowa Medex Co., Ltd. | Method and reagent for the detection or determination of HCV core antigens |
Also Published As
Publication number | Publication date |
---|---|
AU688259B2 (en) | 1998-03-12 |
CA2131028A1 (en) | 1993-09-02 |
EP0628079A1 (en) | 1994-12-14 |
CZ206894A3 (en) | 1995-03-15 |
AU3572593A (en) | 1993-09-13 |
CZ285834B6 (en) | 1999-11-17 |
JPH07504562A (en) | 1995-05-25 |
SK103594A3 (en) | 1995-06-07 |
ZA931299B (en) | 1993-10-13 |
FI943929A (en) | 1994-08-26 |
FI943929A0 (en) | 1994-08-26 |
GB9204274D0 (en) | 1992-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6312889B1 (en) | Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies | |
US5683864A (en) | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies | |
EP0693687B1 (en) | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies | |
US6210675B1 (en) | PT-NANB hepatitis polypeptides | |
EP0644202B1 (en) | Synthetic antigens for the detection of antibodies to hepatitis C virus | |
JP2005124585A (en) | Hepatitis-c virus type 4, 5, and 6 | |
US5229491A (en) | Peptides immunochemically reactive with antibodies directed against hepatitis non-a, non-b virus | |
EP0642666B2 (en) | Hepatitis c assay | |
AU655112B2 (en) | HCV peptide antigens and method of determining HCV | |
WO1993017110A2 (en) | A recombinant hepatitis c virus polypeptide | |
WO1993017111A1 (en) | Hepatitis c virus peptides | |
US20020150990A1 (en) | Hepatitis C virus peptides | |
EP0525910A1 (en) | Non-A, non-B peptide | |
US7166287B1 (en) | Viral agent | |
AU639560C (en) | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies | |
WO1993011158A2 (en) | Non-a, non-b peptides | |
JPH04221398A (en) | Antibody to non-a, non-b hepatitis virus and immunochemically reactive peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CZ FI HU JP KR NO NZ PL SK US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993904270 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 103594 Country of ref document: SK Ref document number: 2131028 Country of ref document: CA Ref document number: PV1994-2068 Country of ref document: CZ Ref document number: 943929 Country of ref document: FI |
|
ENP | Entry into the national phase |
Ref document number: 1994 295721 Country of ref document: US Date of ref document: 19940829 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1993904270 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1994-2068 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1994-2068 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993904270 Country of ref document: EP |